{"id":467137,"date":"2025-12-23T18:23:19","date_gmt":"2025-12-23T18:23:19","guid":{"rendered":"https:\/\/www.europesays.com\/us\/467137\/"},"modified":"2025-12-23T18:23:19","modified_gmt":"2025-12-23T18:23:19","slug":"novo-jumps-on-wegovy-pill-approval","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/467137\/","title":{"rendered":"Novo Jumps on Wegovy Pill Approval"},"content":{"rendered":"\n<p class=\"yf-7hmkaz\">This article first appeared on <a href=\"https:\/\/www.gurufocus.com\/news\/4085198\/novo-jumps-on-wegovy-pill-approval?utm_source=yahoo_finance&amp;utm_medium=syndication&amp;utm_campaign=headlines&amp;r=caf6fe0e0db70d936033da5461e60141\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:GuruFocus;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">GuruFocus<\/a>.<\/p>\n<p class=\"yf-7hmkaz\">Novo Nordisk (<a class=\"link \" href=\"https:\/\/finance.yahoo.com\/quote\/NVO\" data-ylk=\"slk:NYSE:NVO;elm:context_link;itc:0;sec:content-canvas\" rel=\"nofollow noopener\" target=\"_blank\">NYSE:NVO<\/a>)<a href=\"https:\/\/seekingalpha.com\/news\/4534514-novo-nordisk-rises-fda-approves-wegovy-pill-obesity\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:gave investors something to cheer after the FDA;elm:context_link;itc:0;sec:content-canvas\" class=\"link \"> gave investors something to cheer after the FDA<\/a> approved a pill version of its blockbuster weight-loss drug Wegovy, a milestone many patients have been waiting for.<\/p>\n<p class=\"yf-7hmkaz\">The approval makes Wegovy the first GLP-1 treatment in pill form cleared specifically for obesity, offering an alternative for people reluctant to use injections. The FDA decision was backed by results from the OASIS 4 trial, which showed patients taking oral semaglutide 25 mg daily achieved an average weight loss of 16.6%. The study focused on adults who were obese or overweight and had at least 1 related health condition, highlighting just how large the potential patient base could be.<\/p>\n<p class=\"yf-7hmkaz\">Novo expects the Wegovy pill to launch in January 2026, setting up a major expansion of its obesity franchise. Markets reacted quickly, with Novo shares jumping about 9% in after-hours trading.<\/p>\n<p class=\"yf-7hmkaz\">pills lower the barrier to starting treatment and could dramatically widen access to weight-loss therapy. Investors will be watching how quickly demand ramps once the oral version hits the market.<\/p>\n","protected":false},"excerpt":{"rendered":"This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) gave investors something to cheer after the FDA approved&hellip;\n","protected":false},"author":3,"featured_media":425289,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[151,17970,210,1060,9412,67,132,68,428],"class_list":{"0":"post-467137","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-fda","9":"tag-gurufocus","10":"tag-health","11":"tag-medication","12":"tag-novo-nordisk","13":"tag-united-states","14":"tag-unitedstates","15":"tag-us","16":"tag-weight-loss"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115770281578788791","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/467137","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=467137"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/467137\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/425289"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=467137"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=467137"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=467137"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}